Evaluation of the Relationship between Favipiravir Use Status and Telogen Effluvium in Patients Diagnosed with COVID-19

    TLDR Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.
    The study investigated the link between Favipiravir (FVP), a COVID-19 treatment drug, and Telogen Effluvium (TE), a common type of hair loss. It included patients aged 18-65 who had been diagnosed with COVID-19 in the past year and were experiencing hair loss. The results showed that the majority of FVP users were women (p = 0.027), and the rate of positive pull tests, used to diagnose TE, was significantly higher among those who did not use FVP (p = 0.026). This suggests that FVP may not influence the development of TE. This is the first study to explore the effect of FVP on alopecia and TE.
    View this study on dergipark.org.tr →

    Cited in this study